文献速递系统性红斑狼疮

中剂量与高剂量初始泼尼松诱导狼疮肾炎缓解的倾向评分匹配分析

Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score-Matched Analysis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-05-24

该研究比较新发狼疮肾炎患者初始泼尼松≤30 mg/天与≥40 mg/天诱导完全肾脏缓解的差异。倾向评分匹配后高剂量组12个月完全缓解率显著更高(61.8% vs 38.2%,P=0.024),2年和3年完全缓解率亦更高,但累积糖皮质激素剂量与损害无差异。

要点

  • 高剂量初始泼尼松(均值48.6 mg/天)12个月完全缓解率优于中剂量(24.2 mg/天)。
  • 2年和3年完全缓解率在高剂量组仍更高,但累积激素剂量和损害无差异。
  • 两组激素相关损害均随时间加速,提示需快速减量并探索替代策略。

核心结论

  • 新发狼疮肾炎患者初始泼尼松高剂量(中位45 mg/天)较中剂量在12个月时获得显著更高的完全肾脏缓解率。
  • 2年和3年时累积糖皮质激素剂量与损害累积在两组间无差异,但损害在狼疮肾炎晚期更突出。

研究设计与样本

  • 倾向评分匹配分析,纳入新发狼疮肾炎并接受标准免疫抑制治疗且随访至少12个月的患者。
  • 分为中剂量组(≤30 mg/天,n=103,均值24.2±4.6 mg/天)和高剂量组(≥40 mg/天,n=103,均值48.6±12.3 mg/天)。
  • 完全肾脏缓解定义为蛋白尿<0.5 gm/天且肾功能无恶化。

主要发现

  • 12个月完全缓解率:高剂量组61.8% vs 中剂量组38.2%(P=0.024)。
  • 2年完全缓解率:高剂量组67.8% vs 中剂量组39%(P=0.002)。
  • 3年完全缓解率:高剂量组64.9% vs 中剂量组49.1%(P=0.025)。
  • 亚组分析(联用免疫抑制治疗、增殖性/非增殖性狼疮肾炎)中缓解率差异一致。
  • 2年和3年累积糖皮质激素剂量两组相当,同期激素相关损害在两组均加速。

关键数值与推荐

  • 完全肾脏缓解定义:蛋白尿<0.5 gm/天且肾功能无恶化。
  • 中剂量组泼尼松≤30 mg/天(均值24.2±4.6 mg/天),高剂量组≥40 mg/天(均值48.6±12.3 mg/天)。

临床怎么用

  • 对新发狼疮肾炎患者,初始泼尼松高剂量(约45 mg/天)可能较中剂量更有利于12个月内达到完全肾脏缓解。
  • 需关注激素相关损害随时间累积,应快速减量并考虑替代策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The existing guidelines for lupus nephritis (LN) recommend initial prednisone doses of 0.3-1.0 mg/kg/day. However, recent studies reported noninferior outcomes with lower doses. The aim of this study was to compare the complete renal response rates in LN patients treated with prednisone ≤30 mg/day or ≥40 mg/day. METHODS: Patients with new-onset LN and standard immunosuppressive treatment were followed for at least 12 months, divided into medium (≤30 mg/day) and high prednisone groups (≥40 mg/day) and matched (propensity score) based on the baseline differences. Complete renal response was defined as proteinuria <0.5 gm/day and no worsening in renal function. Glucocorticoid-related damage was also assessed. RESULTS: High-dose prednisone patients (n = 103; mean ± SD dose 48.6 ± 12.3 mg/day) achieved better rates of complete response compared to the medium group (n = 103; mean ± SD dose 24.2 ± 4.6 mg/day) (61.8% versus 38.2%; P = 0.024) at 12 months. The difference in response rates was reproduced for several subgroups (concomitant immunosuppressive treatment, proliferative/nonproliferative LN). Complete remission rates were higher at 2 years (67.8% versus 39%; P = 0.002) and 3 years (64.9% versus 49.1%; P = 0.025) after LN diagnosis. Cumulative glucocorticoid dose was comparable at 2 and 3 years. Glucocorticoid-related damage was accelerated in both groups for the same period. CONCLUSION: Higher initial prednisone doses (median 45 mg/day) achieved significantly better rates of complete renal response at 12 months in new-onset LN. Cumulative glucocorticoid dose and damage accrual were not different at 2 and 3 years after LN. Damage was more prominent in the late phases of LN in both groups, underlining the importance of rapid tapering and the need to implement alternative strategies.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Tselios K, Gladman DD, Al-Sheikh H, et al. Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score-Matched Analysis. Arthritis Care Res (Hoboken). 2022. PMID: 33662177. doi:10.1002/acr.24592

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。